J
Jiankang Liu
Researcher at Brigham and Women's Hospital
Publications - 40
Citations - 1604
Jiankang Liu is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 16, co-authored 36 publications receiving 1055 citations. Previous affiliations of Jiankang Liu include University of Minnesota & Harvard University.
Papers
More filters
Journal ArticleDOI
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Akshay S. Desai,John J.V. McMurray,Milton Packer,Karl Swedberg,Jean L. Rouleau,Fabian Chen,Jianjian Gong,Adel R. Rizkala,Abdel Brahimi,Brian Claggett,Peter V. Finn,Loren Howard Hartley,Jiankang Liu,Martin Lefkowitz,Victor Shi,Michael R. Zile,Scott D. Solomon +16 more
TL;DR: LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths.
Journal ArticleDOI
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
Lars Lund,Brian Claggett,Jiankang Liu,Carolyn S.P. Lam,Pardeep S. Jhund,Giuseppe M.C. Rosano,Karl Swedberg,Salim Yusuf,Christopher B. Granger,Marc A. Pfeffer,John J.V. McMurray,Scott D. Solomon +11 more
TL;DR: The hypothesis that candesartan improves outcomes in heart failure with mid‐range ejection fraction is tested with a single dose of the drug in patients with HF.
Journal ArticleDOI
Health-Related Quality of Life Outcomes in PARADIGM-HF.
Eldrin F. Lewis,Brian Claggett,John J.V. McMurray,Milton Packer,Martin Lefkowitz,Jean L. Rouleau,Jiankang Liu,Victor Shi,Michael R. Zile,Akshay S. Desai,Scott D. Solomon,Karl Swedberg +11 more
TL;DR: It is demonstrated that sacubitril/valsartan leads to better HRQL in surviving patients with heart failure, with consistency in most domains, and persist during follow-up beyond 8 months.
Journal ArticleDOI
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial
Inder S. Anand,Brian Claggett,Jiankang Liu,Amil M. Shah,Thomas S. Rector,Sanjiv J. Shah,Akshay S. Desai,Eileen O'Meara,Jerome L. Fleg,Marc A. Pfeffer,Bertram Pitt,Scott D. Solomon +11 more
TL;DR: Higher levels of natriuretic peptides were independently associated with an increased risk for TOPCAT's primary endpoint of cardiovascular mortality, aborted cardiac arrest, or hospitalization for HF when analyzed either continuously or grouped by terciles.
Journal ArticleDOI
The frailty syndrome and outcomes in the TOPCAT trial.
Natalie A. Sanders,Mark A. Supiano,Eldrin F. Lewis,Jiankang Liu,Brian Claggett,Marc A. Pfeffer,Akshay S. Desai,Nancy K. Sweitzer,Scott D. Solomon,James C. Fang +9 more
TL;DR: This analysis sought to characterize frailty in a large contemporary HFpEF clinical trial cohort and to evaluate its impact on patient relevant outcomes.